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regardless of a given country’s income. Arte­
rial hypertension rarely occurs as an isolated 
disease and is often accompanied by metabol­
ic disorders (type 2 diabetes, hypercholesterol­
emia, hyperuricemia, obesity) as well as organ­
­related complications in the cardiovascular sys­
tem (ischemic heart disease, heart insufficien­
cy) or the kidneys.3
Hypertension treatment includes lifestyle 
modifications and drug therapy. Patients with 
grade 1 hypertension may begin treatment with 
lifestyle modifications (limiting sodium and al­
cohol consumption, making dietary changes, 
reducing weight, engaging in regular physical 
IntroductIon Elevated blood pressure is 
one of the leading causes of mortality worldwide. 
The incidence of arterial hypertension (AH) in­
creases with age, and bearing in mind the cur­
rent upward trend in life expectancy, an even 
further increase should be expected. It is es­
timated that over 900 million adults around 
the world have AH. According to forecast data, 
there will be approximately 1.5 billion affected 
people by 2025.1 According to the latest edition 
of the NATPOL study conducted in 2011, ap­
proximately 32% of the adult population in Po­
land have AH.2 In fact, the prevalence of the dis­
ease is extremely high throughout the world, 
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AbstrAct
Background Hypertension is one of the most common chronic diseases. The need to undergo indefinite 
treatment combined with the risk of complications affecting the cardiovascular system impose significant 
psychological and somatic burden on the patient. Arterial hypertension (AH) is rarely an isolated disease 
and the most commonly observed comorbidities include metabolic disorders as well as clinically apparent 
complications associated with polypharmacy, which increases the risk of drug ‑induced adverse events.
aims The aim of the study was to determine factors that have an impact on illness acceptance in patients 
with AH.
methods The study included 532 patients diagnosed with AH. A standardized Acceptance of Illness 
Scale questionnaire and a questionnaire prepared by the authors were used. The Acceptance of 
Illness Scale allows to classify the illness acceptance as high (30–40 points), average (19–29 points), 
or low (8–18 points).
results A high level of illness acceptance was noted in 45% of participants and an average level in 46%. 
Patients with different levels of illness acceptance showed disparities in: duration of AH, number of 
cardiovascular and all diseases, frequency of mental disorders, and number of drugs taken. The number 
of cardiovascular diseases was significantly lower in patients with high levels of illness acceptance than 
in those with poor acceptance. Disease duration in patients with a high level of illness acceptance was 
significantly shorter than in patients with average acceptance.
conclusions The level of illness acceptance is correlated with disease duration, number of diseases, 
and number of medications taken.
Key words
acceptance of illness, 
adherence, 
drug ‑related adverse 
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The exclusion criteria were as follows: young­
er than 18 years of age, lack of patient consent, 
dementia acute enough to prevent a participant 
from filling in the questionnaires.
Participation in the study was voluntary, and 
each participant was informed about its purpose 
and methods as well as the possibility of with­
drawing at any stage. The study was approved by 
the Bioethical Committee of Jagiellonian Uni­
versity (no. 1072.6120.261.2017).
The Acceptance of Illness Scale (AIS) and 
a questionnaire designed by the authors were 
used in the study. The Acceptance of Illness 
Scale includes 8 statements describing the con­
sequences of poor health. These come down to 
a recognition of the limitations imposed by 
the disease, lack of self ­sufficiency, sense of 
dependence on other people, especially the pa­
tient’s family, and lower self ­esteem. Each par­
ticipant was awarded a score ranging from 8 to 
40 points. The lower the score, the worse their 
acceptance of their disease. Based on the AIS, 3 
levels of disease acceptance were determined 
as follows: 8 to 18 points denoted a low level of 
illness acceptance; 19 to 29 points, average ac­
ceptance; and 30 to 40 points, high acceptance.
The survey assessing the patient’s social sit­
uation and clinical data included 22 questions. 
Comorbidities reported by the patient were 
confirmed by medical records. The next part of 
the survey focused on adverse drug reactions 
in patients with hypertension. The structured 
history of current or past drug ­related adverse 
events was completed by the patient. The pa­
tient’s compliance with their doctor’s instruc­
tions was assessed on the basis of the patient’s 
own declared regular intake of prescribed medi­
cations. The completeness of the survey was ver­
ified by members of the research team.
statistical analysis The analysis was per­
formed using the R statistical software, ver­
sion 3.5.1 (R Foundation for Statistical Comput­
ing; http://cran.r ­project.org). The normality of 
the distribution of quantitative variables was 
checked by the Shapiro–Wilk test and a visual 
assessment of the histograms. Nominal data are 
presented as numbers with percentages. Ordinal 
data are presented as medians with interquar­
tile ranges (IQRs), and quantitative variables as 
means (SD) with a distribution close to normal or 
medians (IQRs) in other cases. Comparisons be­
tween groups with regard to individual parame­
ters were made using the following: the χ2 test or 
the Fisher exact test for nominal variables as well 
as the t test, the Mann–Whitney test, analysis of 
variance, and the Kruskal–Wallis test for ordi­
nal and quantitative variables, where appropri­
ate. When significant differences were found in 
the Kruskal–Wallis test, the Dunn post hoc test 
with Bonferroni correction was used. The signif­
icance level was set at a P value of 0.05.
activity, quitting smoking). In the case of grade 
2 and grade 3 hypertension, the European So­
ciety of Hypertension and European Society of 
Cardiology guidelines emphasize pharmaco­
therapy as the method of choice together with 
the implementation of lifestyle modifications.3
Chronic diseases force patients to make 
changes in many aspects of their lives and adapt 
to new conditions. Depending on their life ex­
periences and psychological makeup, patients 
either assume the role of a sick person and ac­
cept their illness or deny their condition and re­
ject the role of a patient.4 A chronically ill per­
son has to cope with a sense of loss and its con­
sequences, including the loss of normal physi­
cal fitness, the loss of certain social roles, such 
as having to relinquish previous professional or 
family functions, and the loss of interperson­
al contacts. These consequences are more seri­
ous in people who find it difficult to accept their 
new health status and are unable to cope with 
negative emotions,5 which in turn has a signif­
icant impact on the quality of life of patients 
with AH.6 By accepting their disease, patients 
are able to adapt to the limitations it imposes 
on them, maintain or regain their self ­esteem 
and control over their life, as well as cultivate 
more positive emotions.7
The aim of the study was to determine those 
factors that shape acceptance of illness in pa­
tients with AH and comorbidities, with a particu­
lar emphasis on the possible role of drug ­induced 
adverse events in lowering acceptance of illness.
Methods The study group included patients 
with AH under long ­term care at the 1st Depart­
ment of Cardiology, Interventional Electrocar­
diology and Arterial Hypertension of the Uni­
versity Hospital in Kraków. We included pa­
tients hospitalized in our department or fol­
lowed at the outpatient hypertension depart­
ment from December 2019 to December 2020. 
The study group included 532 patients with AH 
of whom 314 (59%) were women.
The inclusion criteria for the study were as fol­
lows: older than 18 years of age, diagnosis of AH, 
disease duration exceeding 1 year, and signed 
informed consent to participate in the study. 
whAt’s new?
Since arterial hypertension is a chronic and asymptomatic disease, it can 
adversely affect patients’ acceptance of their illness and, consequently, cause 
a deterioration in their long ‑term compliance with medical advice. At the 
same time, in the vast majority of patients, arterial hypertension is not 
an isolated disease and is often accompanied by other comorbidities or organ 
insufficiency, which itself is a consequence of polypharmacy. In our study, 
we observed that the longer the duration of an illness, the less it was accepted 
by the patient. The level of disease acceptance is significantly lowered also 
by a greater number of comorbidities, received medications, and additionally 
in women, by the occurrence of drug ‑induced adverse events.
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in the following parameters: duration of AH 
(P <0.001), number of cardiovascular diseases 
(P = 0.02), number of all diseases (P <0.001), fre­
quency of mental disorders (mainly anxiety and 
depressive disorders; P = 0.05), and the number 
of drugs taken (P = 0.008), including the number 
of noncardiovascular drugs (P = 0.004). The post 
hoc analysis revealed that disease duration in pa­
tients with a high level of illness acceptance was 
markedly shorter (median, 8 years) than in pa­
tients with an average level of illness acceptance 
(median, 10 years; P <0.001). The number of car­
diovascular diseases was lower in patients with 
a high level of acceptance (median, 1) than in 
those with poor acceptance (median, 2; P = 0.03). 
Furthermore, people with a high level of accep­
tance of their illness had fewer diseases overall 
(median, 2) than those with average (median, 3; 
P <0.001), or poor disease acceptance (median, 4; 
P <0.001). Mental disorders were less common 
among patients with a high level of illness ac­
ceptance (2%) than those with average illness 
acceptance (6%; P = 0.03). Patients with a high 
level of illness acceptance also took fewer non­
cardiovascular drugs than patients with average 
levels (median, 0 and 1, respectively; P = 0.002, 
for both comparisons), and also took fewer med­
ications in general (median, 4 and median, 5, re­
spectively; P = 0.005; TAblE 4). In women, there was 
results The study group included 532 per­
sons, of whom 59% were women and 41% men. 
The mean (SD) age of the study group was 59.95 
(13.52) years (P = 0.001). A difference in body 
weight and height depending on sex was also ob­
served (P <0.001 for both parameters). The medi­
an (IQR) duration of hypertension treatment for 
the group as a whole was 10 (5–18) years, while 
the duration of treatment in the hypertension 
department was 5 (2–10) years (TAblE 1).
The most common comorbidities were dis­
orders of the endocrine system (18% of the en­
tire group), coronary heart disease (13%), and 
respiratory diseases (11%). Atrial fibrillation 
was observed more frequently in men than in 
women (14% and 7%, respectively; P = 0.01), and 
endocrine disorders occurred in women more 
often than in men (24% and 9%, respectively; 
P <0.001; TAblE 2).
A total of 96% of respondents, both women 
and men, reported taking cardiovascular medi­
cations; 94% reported taking at least a single an­
tihypertensive drug. The median (IQR) number 
of antihypertensive pills taken by respondents 
was 2 (1–3) (TAblE 3).
A high level of illness acceptance was noted 
in 242 participants (45%), average in 244 (46%), 
and low in 46 (9%). Patients with different lev­
els of illness acceptance showed disparities 
Table 1 Characteristics of the study population
Parameter Total (n = 532) Women (n = 312) Men (n = 220) P value
Age, y 59.95 (13.52) 61.55 (12.76) 57.69 (14.27) 0.001
Weight, kg 77.5 (68–90) 72 (65–82) 85 (75.75–98) <0.001
Height, cm 168.6 (9.23) 163.58 (7.22) 175.71 (6.76) <0.001
BMI, kg/m2 27.28 (24.45–30.86) 26.85 (24.22–30.83) 27.49 (24.69–30.89) 0.25
Duration of hypertension, y 10 (5–18) 10 (5–20) 10 (5–15) 0.12
Duration of treatment in 
hypertension outpatient clinic, y
5 (2–10) 5 (2–10) 6 (3–10) 0.32
Data are presented as mean (SD) or median (interquartile range).
Table 2 Comorbidities in the study population
Comorbidities associated with 
hypertension
Total (n = 532) Women (n = 312) Men (n = 220) P value
Coronary heart disease 69 (13) 33 (10.6) 36 (16.4) 0.07
Heart failure 29 (5.5) 13 (4.2) 16 (7.3) 0.17
Atrial fibrillation 51 (9.6) 21 (6.7) 30 (13.6) 0.01
Endocrine disorders 95 (17.9) 76 (24.4) 19 (8.6) <0.001
Respiratory diseases 59 (11.1) 35 (11.2) 24 (10.9) >0.99
Mental disorders 20 (3.8) 13 (4.2) 7 (3.2) 0.72
Data are presented as number (percentage) of patients. Comparisons between men and women were made using the χ2 test or the 
Fisher exact test.
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of illness acceptance experienced fewer side ef­
fects (median, 0) than those with average lev­
els (median, 0; P = 0.02).
In men, there was a difference in illness ac­
ceptance levels in relation to the following pa­
rameters: disease duration (P = 0.04), number 
of cardiovascular diseases (P = 0.02), number 
of diseases overall (P <0.001), number of med­
ications taken (P = 0.011), including noncardio­
vascular drugs (P = 0.04), and declared compli­
ance with medical advice (P = 0.05). The post 
hoc analysis showed that disease duration was 
shorter in men with a high level of illness ac­
ceptance (median, 9.5 years) than in those with 
a difference with regard to the impact of disease 
duration (P <0.001; FIgUrE 1A), number of diseases 
overall (P <0.001), and number of side effects (P = 
0.05) on the level of illness acceptance. The post 
hoc analysis showed that women with a high lev­
el of illness acceptance had a shorter disease du­
ration (median, 8 years) than those with an av­
erage (median duration, 10 years; P <0.001) or 
poor level (median duration, 10 years; P = 0.04). 
Women with a high level of illness acceptance 
had fewer diseases overall (median, 3) compared 
with those with an average and poor level (me­
dian, 3 in both groups; P <0.001 and P = 0.02, re­
spectively). Moreover, women with a high level 
Table 3 Pharmacotherapy used in the study population
Pharmacotherapy Total (n = 532) Women (n = 312) Men (n = 220) P value
Main classes of medications
Cardiovascular drugs 508 (95.5) 298 (95.5) 210 (95.5) >0.99
Respiratory drugs 22 (4.1) 12 (3.8) 10 (4.5) 0.86
Nervous system drugs 17 (3.2) 7 (2.2) 10 (4.5) 0.22
Psychotropic drugs 20 (3.8) 11 (3.5) 9 (4.1) 0.92
Dermatological drugs 2 (0.4) 1 (0.3) 1 (0.5) >0.99
Anti ‑diabetic drugs 140 (26.3) 78 (25) 62 (28.2) 0.47
Rheumatologic drugs (glucocorticoids, biological medications) 12 (2.3) 11 (3.5) 1 (0.5) 0.02
Other medications 143 (26.9) 92 (29.5) 51 (23.2) 0.13
Total number of medications taken 5 (3–7) 5 (3–6) 5 (3–7) 0.31
Main classes of cardiovascular drugs
Number of cardiovascular drugs 4 (3–5) 4 (2–5) 4 (3–5) 0.13
Hypertensive drugs (any) 500 (94) 292 (93.6) 208 (94.5) 0.79
ACE inhibitors 282 (53) 163 (52.2) 119 (54.1) 0.74
β ‑Blockers 331 (62.2) 194 (62.2) 137 (62.3) >0.99
Angiotensin receptor blockers 111 (20.9) 74 (23.7) 37 (16.8) 0.07
Calcium channel blockers 223 (41.9) 129 (41.3) 94 (42.7) 0.82
Diuretics 277 (52.1) 157 (50.3) 120 (54.5) 0.38
Other hypertensive drugs 129 (24.2) 69 (22.1) 60 (27.3) 0.21
Number of hypertensive drugs 3 (2–4) 3 (2–3) 3 (2–4) 0.29
Number of hypertensive pills 2 (1–3) 2 (1–3) 2 (1–3) 0.95
Cardiovascular nonhypertensive drugs (any) 363 (68.2) 210 (67.3) 153 (69.5) 0.65
Antiplatelet agents 75 (14.1) 29 (9.3) 46 (20.9) <0.001
Anticoagulants 57 (10.7) 29 (9.3) 28 (12.7) 0.26
Statins 243 (45.7) 135 (43.3) 108 (49.1) 0.22
Other cardiovascular agents 225 (42.3) 137 (43.9) 88 (40) 0.42
Number of cardiovascular nonhypertensive drugs 1 (0–2) 1 (0–2) 1 (0–2) 0.16
Number of cardiovascular nonhypertensive pills 1 (0–2) 1 (0–2) 1 (0–2) 0.16
Data are presented as number (percentage) of patients or median (interquartile range). Comparisons between men and women were made using the χ2 test, Fisher exact 
test, or the Mann–Whitney test.
Abbreviations: ACE, angiotensin ‑converting enzyme
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dIscussIon Despite numerous guidelines on 
the management of hypertension, studies both 
in patients with hypertension and the general 
population indicate that more than half of all 
patients with hypertension remain untreated or 
are inadequately treated, that is, they have not 
reached their target blood pressure values. One of 
the significant causes of insufficient blood pres­
sure control is poor compliance with pharmaco­
therapy (nonadherence), and this issue is prev­
alent in 30% to 50% of patients with hyperten­
sion.8,9 Importantly, many patients make the con­
scious decision to stop taking any medications. 
A better understanding by the patient, including 
knowledge of factors that have an impact on ac­
ceptance of the disease and its treatment, may 
translate into a long ­term improvement in ensur­
ing effective pharmacological treatment of AH.
Our study showed an inverse relationship be­
tween illness acceptance and the duration of AH. 
It was demonstrated that high illness acceptance 
in men is associated with a more frequent and 
regular compliance with medical advice, as de­
clared by the patients. People with high illness 
acceptance have fewer diseases overall. A corre­
lation was likewise observed between high dis­
ease acceptance and fewer medications taken. 
average levels (median, 10 years; P = 0.02). Men 
with a high level of illness acceptance had fewer 
illnesses overall (median, 2) than those with av­
erage and poor levels (median, 4 in both groups; 
P <0.001 for both comparisons; FIgUrE 1b). Men 
with a high level of illness acceptance had fewer 
cardiovascular diseases (median, 1) than those 
with poor levels (median, 2; P = 0.02). Moreover, 
men who accepted their illness took fewer med­
ications and noncardiovascular drugs overall 
(median, 4 and median, 0, respectively) than 
those with average levels of acceptance (medi­
an, 6 and median, 1, respectively; P = 0.004 and 
P = 0.02). Finally, men with a high level of ill­
ness acceptance (98%) declared that they com­
plied with medical advice far more frequent­
ly than those with poor acceptance of their ill­
ness (87%; P = 0.05).
A total of 34% of respondents (40% of women 
and 25% of men) experienced drug intolerance, 
and 8% of women and 5% of men did not tolerate 
any kind of hypertensive medication (P <0.001). 
The number of medications that women could not 
tolerate ranged from 0 to 8, and in men it ranged 
from 0 to 4. A difference was thus observed be­
tween the sexes with regard to the number of drugs 
that patients could not tolerate (P <0.001) (TAblE 5).
Table 4 An analysis of illness acceptance in the study population as a whole
Entire group Acceptance of illness P value P value 
(post hoc test)High (n = 242) Average (n = 244) Low (n = 46)
Sex Female 142 (58.7) 147 (60.2) 23 (50) 0.43 –
Male 100 (41.3) 97 (39.8) 23 (50)
Age, y, mean (SD) 58.86 (14.15) 60.48 (12.96) 62.91 (12.71) 0.13 –
Duration of arterial hypertension, y 8 (5–13.75)a 10 (6–20)a 10 (6.25–18) <0.001 a: <0.001
Number of cardiovascular diseases 1 (1–2)a 2 (1–2) 2 (1–3)a 0.02 a: 0.03
Number of all diseases 2 (2–4)a,b 3 (2–5)a 4 (2.25–6)b <0.001 a: <0.001; 
b: <0.001
Mental disorders 4 (1.7)a 14 (5.7)a 2 (4.3) 0.046 a: 0.03
Number of cardiovascular drugs 4 (2–5) 4 (3–5) 4 (3–5) 0.38
Number of noncardiovascular drugs 0 (0–1)a 1 (0–2)a 1 (0–2) 0.004 a: 0.002
Number of all medications 4 (3–6)a 5 (3–7)a 5 (3.25–7) 0.008 a: 0.005
Number of hypertensive drugs 3 (2–4) 3 (2–3.25) 3 (2–3) 0.95 –
Number of hypertensive pills 2 (1–3) 2 (1–3) 2 (1.25–3) 0.15 –
Number of cardiovascular nonhypertensive drugs 1 (0–2) 1 (0–2) 1 (1–2) 0.09 –
Number of cardiovascular nonhypertensive pills 1 (0–2) 1 (0–2) 1 (1–2) 0.09 –
Number of nontolerated medications 0 (0–1) 0 (0–1) 0 (0–1) 0.09 –
Drug intolerance 70 (28.9) 93 (38.1) 15 (32.6) 0.1 –
Number of adverse effects 0 (0–1) 0 (0–2) 0 (0–1) 0.06 –
Adverse effects 69 (28.5) 93 (38.1) 15 (32.6) 0.08 –
Compliance with medical advice 235 (97.1) 230 (94.3) 43 (93.5) 0.25 –
Data are presented as number (percentage) of patients or median (interquartile range) unless indicated otherwise. The group comparisons were based on the χ2 test 
or Fisher exact test in the case of nominal data and on the analysis of variance or the Kruskal–Wallis test for quantitative data.
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the physician assumes a proportionally greater 
role as a source of information on the disease.11
The  relationship between the  occurrence 
of adverse effects and poor illness accep­
tance observed in women may be the result of 
an emotion ­focused stress coping strategy seen 
in patients with AH, which may also translate 
into selective use of medications, and as a result, 
poorer compliance with medical advice.12,13 There 
are no data on differences between the sexes in 
terms of how patients with hypertension cope 
with stress. However, population studies have 
revealed that health ­related quality of life is low­
er in women with hypertension than in men of 
the same age.14,15 The key to ensure an effective 
relationship between a physician and patient is 
appropriately selected antihypertensive treat­
ment that does not produce adverse effects. Each 
time a patient visits a cardiology clinic, the phy­
sician should ask the patient how he/she is tol­
erating the medications prescribed.
In our study, we noted a correlation between 
a higher level of illness acceptance in patients 
with AH and greater compliance with medical 
advice. In another study in a similar sample size, 
it was also demonstrated that among hyperten­
sive patients with high compliance rates, there 
was a higher proportion of patients with high 
Moreover, in women, we found a relationship be­
tween poor illness acceptance and a higher inci­
dence of drug ­induced adverse events.
In a systematic review of 53 studies on pa­
tients’ understanding of hypertension and their 
experiences with AH treatment, Marshall et al10 
showed that in questionnaires, respondents with 
this disease often chose statements which indi­
cated that they were unaware of the chronic na­
ture of hypertension, and often paid special at­
tention to the risk of drug ­related adverse events. 
Our results confirm a correlation between great­
er acceptance of AH and shorter disease dura­
tion. In addition, we observed lower levels of ill­
ness acceptance in women who had experienced 
adverse drug ­induced events. This does indicate, 
however, that patients with AH should be con­
tinuously educated about their disease. In addi­
tion to the information they receive when hyper­
tension is first diagnosed and pharmacotherapy 
begins, a patient should be informed once more 
during their next contact with a physician about 
the chronic nature of the disease and the need 
to continue taking medications. Several­year­
long follow­up of patients with hypertension has 
shown that the longer the duration of the dis­
ease, the less likely the patient is to search for 
information about AH themselves, and hence 
Table 5 Drug intolerance in the study population
Intolerance of following medications Total (n = 532) Women (n = 312) Men (n = 220) P value
Intolerance of any kind of medication 178 (33.5) 124 (39.7) 54 (24.5) <0.001
Intolerance of any kind of antihypertensive medication 37 (7) 26 (8.3) 11 (5) <0.001
Number of medications not 
tolerated by the patients
0 354 (66.5) 188 (60.3) 166 (75.5) <0.001
1–2 136 (25.6) 93 (29.8) 43 (19.5) –
3–5 40 (7.5) 29 (9.3) 11 (5) –
>5 2 (0.4) 2 (0.6) 0 (0) –
Intolerance of cardiovascular agents
ACE inhibitors 11 (2.1) 8 (2.6) 3 (1.4) 0.54
β ‑Blockers 9 (1.7) 7 (2.2) 2 (0.9) 0.32
Sartans 6 (1.1) 4 (1.3) 2 (0.9) >0.99
Calcium channel blockers 12 (2.3) 7 (2.2) 5 (2.3) >0.99
Diuretics 7 (1.3) 4 (1.3) 3 (1.4) >0.99
Other hypertensive medications 13 (2.4) 9 (2.9) 4 (1.8) 0.57
Anticoagulants 6 (1.1) 3 (1) 3 (1.4) 0.7
Statins 6 (1.1) 5 (1.6) 1 (0.5) 0.409
Other cardiovascular drugs 15 (2.8) 10 (3.2) 5 (2.3) 0.603
Drug intolerance (other medications)
Analgesics 30 (5.6) 26 (8.3) 4 (1.8) 0.001
Other medications 116 (21.8) 78 (25) 38 (17.3) 0.04
Data are presented as number (percentage) of patients. Comparisons between men and women were made using the χ2 test, the Fisher exact test, or the Mann–Whitney test.
Abbreviations: see TAblE 3
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on our experience, men with high levels of ill­
ness acceptance were much more likely to de­
clare that they complied with medical advice 
and take their prescribed medications regularly. 
A study by Qiu et al20 similarly showed a positive 
correlation between illness acceptance and pro­
­health behavior in terms of the nonpharmaco­
logical and pharmacological management of AH.
conclusions Based on our results, it can be 
stated that shorter duration of AH is associated 
with a higher level of illness acceptance. More­
over, we demonstrated a correlation between 
the level of illness acceptance and the number of 
diseases that a patient has overall. The fewer dis­
eases, the higher the level of illness acceptance. 
Also, the fewer medications taken, the higher 
the level of illness acceptance. The occurrence 
of drug ­induced side effects has a negative im­
pact on illness acceptance in women. High lev­
els of illness acceptance in men with hyperten­
sion are associated with more frequent compli­
ance with medical advice. Lastly, there is no re­
lationship between illness acceptance and pa­
tients’ age or sex.
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